Metabolic Syndrome

Endocrinology and Metabolism Clinics of North America - Tập 43 Số 1 - Trang 1-23 - 2014
Susan L. Samson1, Alan J. Garber2,3,4
1Department of Medicine, Baylor College of Medicine, One Baylor Plaza, ABBR R615, Houston, TX 77030, USA
2Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA
3Department of Medicine, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA
4Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rossner, 2009, Eskil Kylin (1885–1974), Obes Rev, 10, 362, 10.1111/j.1467-789X.2008.00531.x

Vague, 1956, The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease, Am J Clin Nutr, 4, 20, 10.1093/ajcn/4.1.20

Oda, 2012, Metabolic syndrome: its history, mechanisms, and limitations, Acta Diabetol, 49, 89, 10.1007/s00592-011-0309-6

Haller, 1977, Epidemiology and associated risk factors of hyperlipoproteinemia, Z Gesamte Inn Med, 32, 124

Singer, 1977, Diagnosis of primary hyperlipoproteinemias, Z Gesamte Inn Med, 32, 129

Phillips, 1978, Sex hormones, risk factors and cardiovascular disease, Am J Med, 65, 7, 10.1016/0002-9343(78)90685-X

Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diabetes.37.12.1595

WHO obesity and overweight fact sheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed October 23, 2013.

Hossain, 2007, Obesity and diabetes in the developing world–a growing challenge, N Engl J Med, 356, 213, 10.1056/NEJMp068177

Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

Balkau, 1999, Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diabet Med, 16, 442, 10.1046/j.1464-5491.1999.00059.x

Einhorn, 2003, American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract, 9, 237

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

Available at: http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf. Accessed October 23, 2013.

Grundy, 2004, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition, Arterioscler Thromb Vasc Biol, 24, e13, 10.1161/01.ATV.0000111245.75752.C6

Alberti, 2006, Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation, Diabet Med, 23, 469, 10.1111/j.1464-5491.2006.01858.x

Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644

Marcovecchio, 2013, Metabolic syndrome in youth: chimera or useful concept?, Curr Diab Rep, 13, 56, 10.1007/s11892-012-0331-2

Cook, 2003, Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994, Arch Pediatr Adolesc Med, 157, 821, 10.1001/archpedi.157.8.821

Zimmet, 2007, The metabolic syndrome in children and adolescents–an IDF consensus report, Pediatr Diabetes, 8, 299, 10.1111/j.1399-5448.2007.00271.x

Beltran-Sanchez, 2013, Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010, J Am Coll Cardiol, 62, 697, 10.1016/j.jacc.2013.05.064

Gao, 2008, Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk?, Int J Obes (Lond), 32, 757, 10.1038/sj.ijo.0803797

Pandit, 2012, Metabolic syndrome in South Asians, Indian J Endocrinol Metab, 16, 44, 10.4103/2230-8210.91187

Mabry, 2010, Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review, Diabet Med, 27, 593, 10.1111/j.1464-5491.2010.02998.x

Lee, 2013, Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey, Int J Cardiol, 166, 633, 10.1016/j.ijcard.2011.11.095

Unno, 2012, The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome–the results of the Kyushu and Okinawa Population Study (KOPS), J Atheroscler Thromb, 19, 462, 10.5551/jat.11528

Gu, 2005, Prevalence of the metabolic syndrome and overweight among adults in China, Lancet, 365, 1398, 10.1016/S0140-6736(05)66375-1

Wilson, 2005, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus, Circulation, 112, 3066, 10.1161/CIRCULATIONAHA.105.539528

Scuteri, 2005, The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study, Diabetes Care, 28, 882, 10.2337/diacare.28.4.882

Sattar, 2008, Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies, Lancet, 371, 1927, 10.1016/S0140-6736(08)60602-9

Liu, 2013, Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001–2010, PLoS One, 8, e66233, 10.1371/journal.pone.0066233

Cook, 2008, Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002, J Pediatr, 152, 165, 10.1016/j.jpeds.2007.06.004

Monzani, 2013, Metabolic syndrome is strictly associated with parental obesity beginning from childhood, Clin Endocrinol (Oxf), 10.1111/cen.12261

Randeva, 2012, Cardiometabolic aspects of the polycystic ovary syndrome, Endocr Rev, 33, 812, 10.1210/er.2012-1003

Apridonidze, 2005, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 1929, 10.1210/jc.2004-1045

Glueck, 2003, Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome, Metabolism, 52, 908, 10.1016/S0026-0495(03)00104-5

Moran, 2010, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 16, 347, 10.1093/humupd/dmq001

Carmina, 2006, Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS, Eur J Endocrinol, 154, 141, 10.1530/eje.1.02058

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum Reprod, 19, 41, 10.1093/humrep/deh098

Gutierrez, 2012, Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management, Endocrine, 41, 1, 10.1007/s12020-011-9565-z

Krishnan, 2012, Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals, J Acquir Immune Defic Syndr, 61, 381, 10.1097/QAI.0b013e3182690e3c

Samaras, 2007, Diabetes Care, 30, 113, 10.2337/dc06-1075

Alencastro, 2012, Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions, AIDS Res Ther, 9, 29, 10.1186/1742-6405-9-29

Freitas, 2011, Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients, BMC Infect Dis, 11, 246, 10.1186/1471-2334-11-246

Verhelst, 2011, Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis, Eur J Endocrinol, 165, 881, 10.1530/EJE-11-0599

Attanasio, 2010, Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement, J Clin Endocrinol Metab, 95, 74, 10.1210/jc.2009-1326

Kahn, 2007, Metabolic syndrome: is it a syndrome? Does it matter?, Circulation, 115, 1806, 10.1161/CIRCULATIONAHA.106.658336

Boronat, 2009, Differences in traditional and emerging cardiovascular risk factors of subjects discordantly classified by metabolic syndrome definitions of the International Diabetes Federation and the National Cholesterol Education Program, Nutr Metab Cardiovasc Dis, 19, 417, 10.1016/j.numecd.2008.07.010

Eddy, 2008, The metabolic syndrome and cardiovascular risk: implications for clinical practice, Int J Obes (Lond), 32, S5, 10.1038/ijo.2008.28

Fedorowski, 2009, The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in Malmö evaluation study), J Hypertens, 27, 109, 10.1097/HJH.0b013e328314b80a

Milionis, 2007, Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects, Int J Clin Pract, 61, 545, 10.1111/j.1742-1241.2006.01269.x

Nilsson, 2007, The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects–a population-based study comparing three different definitions, Diabet Med, 24, 464, 10.1111/j.1464-5491.2007.02142.x

Jeppesen, 2007, Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study, J Am Coll Cardiol, 49, 2112, 10.1016/j.jacc.2007.01.088

Wilson, 2008, Cardiometabolic risk: a Framingham perspective, Int J Obes (Lond), 32, S17, 10.1038/ijo.2008.30

Eberly, 2006, Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial, Diabetes Care, 29, 123, 10.2337/diacare.29.01.06.dc05-1320

Cull, 2007, Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78, Circulation, 116, 2119, 10.1161/CIRCULATIONAHA.107.733428

Bruno, 2004, Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study, Diabetes Care, 27, 2689, 10.2337/diacare.27.11.2689

Kahn, 2005, The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 48, 1684, 10.1007/s00125-005-1876-2

Laakso, 1999, Hyperglycemia and cardiovascular disease in type 2 diabetes, Diabetes, 48, 937, 10.2337/diabetes.48.5.937

Ford, 2008, Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study, Cardiovasc Diabetol, 7, 35, 10.1186/1475-2840-7-35

Ford, 2008, Metabolic syndrome and incident diabetes: current state of the evidence, Diabetes Care, 31, 1898, 10.2337/dc08-0423

Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94

Wannamethee, 2005, Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus, Arch Intern Med, 165, 2644, 10.1001/archinte.165.22.2644

Cameron, 2008, The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study, J Intern Med, 264, 177, 10.1111/j.1365-2796.2008.01935.x

Krawczyk, 2010, Nonalcoholic fatty liver disease, Best Pract Res Clin Gastroenterol, 24, 695, 10.1016/j.bpg.2010.08.005

Starley, 2010, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, Hepatology, 51, 1820, 10.1002/hep.23594

Smits, 2013, Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups, J Gastroenterol Hepatol, 28, 664, 10.1111/jgh.12106

Castro-Martinez, 2012, Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome, Cir Cir, 80, 128

Caballeria, 2012, Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used, Eur J Gastroenterol Hepatol, 24, 1007, 10.1097/MEG.0b013e328355b87f

Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423

Gilbert, 2013, Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression, Annu Rev Med, 64, 45, 10.1146/annurev-med-121211-091527

Giovannucci, 2010, Diabetes and cancer: a consensus report, CA Cancer J Clin, 60, 207, 10.3322/caac.20078

Oda, 2008, The metabolic syndrome as a concept of adipose tissue disease, Hypertens Res, 31, 1283, 10.1291/hypres.31.1283

Bremer, 2013, Adipose tissue dysfunction in nascent metabolic syndrome, J Obes, 2013, 393192

Fox, 2007, Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study, Circulation, 116, 39, 10.1161/CIRCULATIONAHA.106.675355

Neeland, 2012, Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults, Obesity (Silver Spring), 21, E439, 10.1002/oby.20135

Bergman, 2006, Why visceral fat is bad: mechanisms of the metabolic syndrome, Obesity (Silver Spring), 14, 16S, 10.1038/oby.2006.277

Bergman, 2007, Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk, Am J Med, 120, S3, 10.1016/j.amjmed.2006.11.012

Klop, 2013, Dyslipidemia in obesity: mechanisms and potential targets, Nutrients, 5, 1218, 10.3390/nu5041218

Nikolic, 2013, Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches, Nutrients, 5, 928, 10.3390/nu5030928

Subramanian, 2012, Hypertriglyceridemia secondary to obesity and diabetes, Biochim Biophys Acta, 1821, 819, 10.1016/j.bbalip.2011.10.003

Gupta, 2010, Metabolic syndrome: what are the risks for humans?, Biosci Trends, 4, 204

Reaven, 2011, Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences, J Clin Hypertens (Greenwich ), 13, 238, 10.1111/j.1751-7176.2011.00439.x

Andreassi, 2009, Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction, Mutat Res, 667, 35, 10.1016/j.mrfmmm.2008.10.018

Landsberg, 2013, Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment–a position paper of the Obesity Society and the American Society of Hypertension, Obesity (Silver Spring), 21, 8, 10.1002/oby.20181

Kershaw, 2004, Adipose tissue as an endocrine organ, J Clin Endocrinol Metab, 89, 2548, 10.1210/jc.2004-0395

Matsuzawa, 2011, The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism, J Atheroscler Thromb, 18, 629, 10.5551/jat.7922

West, 2009, Dead adipocytes and metabolic dysfunction: recent progress, Curr Opin Endocrinol Diabetes Obes, 16, 178, 10.1097/MED.0b013e3283292327

Cinti, 2005, Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans, J Lipid Res, 46, 2347, 10.1194/jlr.M500294-JLR200

Semenkovich, 2006, Insulin resistance and atherosclerosis, J Clin Invest, 116, 1813, 10.1172/JCI29024

Lusis, 2008, Metabolic syndrome: from epidemiology to systems biology, Nat Rev Genet, 9, 819, 10.1038/nrg2468

Phillips, 2013, Metabolically healthy obesity: definitions, determinants and clinical implications, Rev Endocr Metab Disord, 14, 219, 10.1007/s11154-013-9252-x

O'Connell, 2010, The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity, PLoS One, 5, e9997, 10.1371/journal.pone.0009997

O'Connell, 2011, Preadipocyte factor-1 is associated with metabolic profile in severe obesity, J Clin Endocrinol Metab, 96, E680, 10.1210/jc.2010-2026

Povel, 2011, Genetic variants and the metabolic syndrome: a systematic review, Obes Rev, 12, 952, 10.1111/j.1467-789X.2011.00907.x

Jin, 2008, The WNT signalling pathway and diabetes mellitus, Diabetologia, 51, 1771, 10.1007/s00125-008-1084-y

Ingelsson, 2010, Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans, Diabetes, 59, 1266, 10.2337/db09-1568

Lyssenko, 2007, Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes, J Clin Invest, 117, 2155, 10.1172/JCI30706

Florez, 2006, TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program, N Engl J Med, 355, 241, 10.1056/NEJMoa062418

Phillips, 2012, Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome, J Nutr Biochem, 23, 239, 10.1016/j.jnutbio.2010.11.020

Warodomwichit, 2009, Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial lipemia, J Nutr, 139, 439

Loos, 2005, Gene-diet interactions on body weight changes, J Am Diet Assoc, 105, S29, 10.1016/j.jada.2005.02.015

Loos, 2008, Common variants near MC4R are associated with fat mass, weight and risk of obesity, Nat Genet, 40, 768, 10.1038/ng.140

Loos, 2008, FTO: the first gene contributing to common forms of human obesity, Obes Rev, 9, 246, 10.1111/j.1467-789X.2008.00481.x

Frayling, 2007, A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity, Science, 316, 889, 10.1126/science.1141634

Scuteri, 2007, Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits, PLoS Genet, 3, e115, 10.1371/journal.pgen.0030115

Kooner, 2008, Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides, Nat Genet, 40, 149, 10.1038/ng.2007.61

Grundy, 2004, Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management, Arterioscler Thromb Vasc Biol, 24, e19, 10.1161/01.ATV.0000112379.88385.67

Yamaoka, 2012, Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis, BMC Med, 10, 138, 10.1186/1741-7015-10-138

Orchard, 2013, Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study, Diabet Med, 30, 46, 10.1111/j.1464-5491.2012.03750.x

Kramer, 2009, Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery, Am J Prev Med, 37, 505, 10.1016/j.amepre.2009.07.020

Perreault, 2012, Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study, Lancet, 379, 2243, 10.1016/S0140-6736(12)60525-X

Potenza, 2009, The metabolic syndrome: definition, global impact, and pathophysiology, Nutr Clin Pract, 24, 560, 10.1177/0884533609342436

Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet, 380, 565, 10.1016/S0140-6736(12)61190-8

Gotto, 2013, Pharmacotherapies for lipid modification: beyond the statins, Nat Rev Cardiol, 10, 560, 10.1038/nrcardio.2013.117

Boekholdt, 2013, Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis, Circulation, 128, 1504, 10.1161/CIRCULATIONAHA.113.002670

1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021

AIM-HIGH Investigators, 2011, Am Heart J, 161, 538, 10.1016/j.ahj.2010.12.007

Guyton, 2013, Relationship of lipoproteins to cardiovascular events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial, J Am Coll Cardiol

HPS2-THRIVE Collaborative Group, 2013, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055

Ginsberg, 2007, Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 56i, 10.1016/j.amjcard.2007.03.024

Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282

Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604

Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560

Knowler, 2009, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study, Lancet, 374, 1677, 10.1016/S0140-6736(09)61457-4

Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512

Kahn, 2005, The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 28, 2289, 10.2337/diacare.28.9.2289

Haffner, 2006, The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease, Am J Cardiol, 97, 3A, 10.1016/j.amjcard.2005.11.010

Simmons, 2010, The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation, Diabetologia, 53, 600, 10.1007/s00125-009-1620-4

Kohli, 2006, Role of the metabolic syndrome in risk assessment for coronary heart disease, JAMA, 295, 819, 10.1001/jama.295.7.819